TURKEY MEDICAL CANNABIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The turkey medical cannabis market is estimated to be valued at USD 140.7 Mn in 2025 and is expected to reach USD 430.2 Mn by 2032, exhibiting  a compound annual growth rate (CAGR) of 16.5% from 2025 to 2032. Turkey medical cannabis market represents a significant emerging opportunity within the broader European medical cannabis landscape, reflecting the country's strategic positioning between Europe and Asia as well as its progressive approach toward medical cannabis regulation. The Turkish government has implemented a comprehensive legal framework that permits the cultivation, production, and distribution of medical cannabis products for therapeutic purposes, marking a substantial shift from traditional cannabis prohibition policies. This regulatory evolution has created a conducive environment for both domestic and international pharmaceutical companies to establish operations and develop cannabis-based medical products.

The market encompasses various product categories including oils, capsules, tinctures, and other pharmaceutical preparations derived from cannabis plants, primarily focusing on conditions such as epilepsy, chronic pain, multiple sclerosis, and cancer-related symptoms. Turkey's robust pharmaceutical manufacturing infrastructure, combined with favorable climatic conditions for cannabis cultivation and a growing patient population seeking alternative treatment options, positions the country as a potential regional hub for medical cannabis production and distribution. The market dynamics are further influenced by increasing healthcare expenditure, rising awareness about medical cannabis benefits among healthcare professionals, and the government's commitment to developing a regulated medical cannabis industry that meets international quality standards.

Market Dynamics

The Turkey medical cannabis market is driven by several compelling factors that collectively create a robust growth environment for industry stakeholders and healthcare providers. Primary market drivers include the Turkish government's progressive regulatory framework that provides clear guidelines for medical cannabis cultivation, production, and distribution, thereby reducing regulatory uncertainty and encouraging investment from pharmaceutical companies and cultivators. The increasing prevalence of chronic diseases such as cancer, epilepsy, multiple sclerosis, and chronic pain conditions has created substantial demand for alternative therapeutic options, with medical cannabis emerging as a viable treatment modality supported by growing clinical evidence. Additionally, rising healthcare awareness among Turkish patients and healthcare professionals about the therapeutic benefits of cannabis-based medicines has accelerated market acceptance and adoption rates.

However, the market faces significant restraints including social stigma associated with cannabis use, limited patient access due to restrictive prescription protocols, high costs of medical cannabis products that may not be covered by insurance systems, and complex regulatory compliance requirements that can burden smaller market entrants. Furthermore, the lack of comprehensive clinical research data specific to the Turkish population and limited healthcare professional training on medical cannabis prescribing practices pose additional challenges. Despite these restraints, substantial opportunities exist within the market, particularly in establishing Turkey as a regional export hub for medical cannabis products to neighboring countries and European markets, leveraging the country's strategic geographical location and existing pharmaceutical manufacturing capabilities. The potential for expanding product portfolios to include innovative delivery methods and formulations, coupled with opportunities for research partnerships between Turkish institutions and international cannabis companies, presents significant growth prospects.

Key Features of the Study

• This report provides in-depth analysis of the Turkey medical cannabis market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Turkey medical cannabis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Kenevirco, Pharmananda Pharmaceuticals, Aurora Cannabis Inc., Organigram Holdings Inc., Cronos Group Inc., Curaleaf Holdings Inc., and Other Prominent Players
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Turkey medical cannabis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Turkey medical cannabis market

Market Segmentation

• Product Type Insights (Revenue, USD Mn, 2020 - 2032)
  • Oils and Extracts
  • Dried Flower
  • Capsules and Tablets
  • Topicals and Creams
• Derivative Insights (Revenue, USD Mn, 2020 - 2032)
  • Cannabidiol (CBD)
  • Tetrahydrocannabinol (THC)
  • Balanced CBD–THC
  • Other Cannabinoids
• Application Insights (Revenue, USD Mn, 2020 - 2032)
  • Pain Management
  • Neurological Disorders (Epilepsy, Multiple Sclerosis, Parkinson’s, etc.)
  • Mental Health Disorders (Anxiety, Depression, PTSD)
  • Cancer Treatment Support (Nausea, Appetite Stimulation)
  • Chronic Diseases (Arthritis, Diabetes complications, etc.)
  • Other Therapeutic Uses
• Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Patients (Individual Consumers)
  • Research and Academic Institutions
  • Healthcare Providers / Clinics
  • Pharmaceutical Companies
• Key Players Insights
  • Kenevirco
  • Pharmananda Pharmaceuticals
  • Aurora Cannabis Inc.
  • Organigram Holdings Inc.
  • Cronos Group Inc.
  • Curaleaf Holdings Inc.
  • Other Prominent Players